IgGenix Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$40M
- Investors
-
11
IgGenix General Information
Description
Developer of an antibody-based therapeutic platform intended to speed up the clinical response time against allergies. The company's platform engineers antibodies to capture allergens and endow them with powerful immune-modulating activities derived from the immunoglobulin G (IgG) antibody class, enabling the medical industry to combat life-threatening allergic reactions and cascades.
Contact Information
Website
www.iggenix.comCorporate Office
- 681 Gateway Boulevard
- Floor 4
- South San Francisco, CA 94080
- United States
Corporate Office
- 681 Gateway Boulevard
- Floor 4
- South San Francisco, CA 94080
- United States
IgGenix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 02-Feb-2023 | $40M | Completed | Clinical Trials - Phase 1 | ||
| 2. Early Stage VC (Series A1) | 26-Jul-2021 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC (Series A) | 04-Aug-2020 | $10M | $10M | Completed | Clinical Trials - Phase 1 |
IgGenix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 4,000,000 | $0.000010 | $0.1 | $1.25 | $1.25 | 1x | $1.25 | 11.52% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
IgGenix Comparisons
Industry
Financing
Details
IgGenix Competitors (33)
One of IgGenix’s 33 competitors is Immunomic Therapeutics, a Venture Capital-Backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immunomic Therapeutics | Venture Capital-Backed | Rockville, MD | ||||
| Actym Therapeutics | Venture Capital-Backed | Berkeley, CA | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Byondis | Corporation | Nijmegen, Netherlands |
IgGenix Patents
IgGenix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023375308-A1 | Compositions and methods for treating and suppressing allergic responses | Pending | 09-Nov-2022 | ||
| EP-4615503-A2 | Compositions and methods for treating and suppressing allergic responses | Pending | 09-Nov-2022 | ||
| EP-4615503-A4 | Compositions and methods for treating and suppressing allergic responses | Pending | 09-Nov-2022 | ||
| US-20250263472-A1 | Compositions and methods for treating and suppressing allergic responses | Pending | 09-Nov-2022 | ||
| WO-2024102700-A2 | Compositions and methods for treating and suppressing allergic responses | Inactive | 09-Nov-2022 | C07K16/16 |
IgGenix Signals
IgGenix Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| FemHealth Ventures | Venture Capital | Minority | ||
| Lilly USA | Corporation | Minority | ||
| Medical Incubator Japan | Venture Capital | Minority | ||
| SBI Investment | Venture Capital | Minority | ||
| Angel (individual) | Minority |
IgGenix FAQs
-
When was IgGenix founded?
IgGenix was founded in 2019.
-
Where is IgGenix headquartered?
IgGenix is headquartered in South San Francisco, CA.
-
What is the size of IgGenix?
IgGenix has 8 total employees.
-
What industry is IgGenix in?
IgGenix’s primary industry is Drug Discovery.
-
Is IgGenix a private or public company?
IgGenix is a Private company.
-
What is the current valuation of IgGenix?
The current valuation of IgGenix is .
-
What is IgGenix’s current revenue?
The current revenue for IgGenix is .
-
How much funding has IgGenix raised over time?
IgGenix has raised $75M.
-
Who are IgGenix’s investors?
FemHealth Ventures, Lilly USA, Medical Incubator Japan, SBI Investment, and are 5 of 11 investors who have invested in IgGenix.
-
Who are IgGenix’s competitors?
Immunomic Therapeutics, Actym Therapeutics, Adimab, CytomX Therapeutics, and Byondis are some of the 33 competitors of IgGenix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process